Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a registered direct offering and a concurrent private ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Bayer Leverkusen coach Xabi Alonso wants his players to give one last big push as they look to crown an intense phase of nine ...

This is an extended version of the interview by FOX 13 News reporter Chris Reed with Liberty Village Chairman Lex Howard and President Dennis Leavitt.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Watch a bright Moon dominate the sky, trace the Winter Hexagon, and continue enjoying the evening parade of planets in the ...

Nuvectis is also advancing NXP900 for YES1/SRC-expressing solid tumors, with promising early data showing no dose-limiting ...

To get a Golden Age in Civilization 7, all you have to do is completing any Legacy Path during the Antiquity Age or ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

James Bay Minerals’ (ASX:JBY) drilling highlights ‘exciting’ potential for future drilling beneath high-grade rock samples at ...